6.41
+3.55%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Embecta
From its filings with the US Securities and Exchange Commission
Embecta is based in Parsippany, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EMBC. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 30 September 2025, it reported revenue of $1.08bn and net income of $95.4m. At that date it held total assets of $1.09bn and shareholders' equity of −$650.6m. By business, Pen Needles brought in 72.6% of revenue, followed by Safety at 12.8% and Syringes at 11.5%. By region, United States accounted for 53.6%, followed by International at 46.4%.
Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes.
We have a broad portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Our conventional pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. We also sell safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Our conventional and safety pen needles are compatible and frequently used with widely available pen injectors in the market today. In addition to pen needles, we sell sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. We also sell safety insulin syringes, which have a sliding safety arm that can be activated with one-hand after the injection to help protect healthcare workers from needlestick injuries.
Quoted from its 10-K, filed 25 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 21 Mar 2022
- Employees
- 1,850
- Website
- embecta.com ↗
- Head office
- 300 KIMBALL DRIVE, PARSIPPANY, NJ, 07054
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Devdatt KurdikarChairman of the Board, President, Chief Executive Officer, since 2022$9.4m
- Mr. Jacob ElguiczeChief Financial Officer, Senior Vice President$3.5m
- Ms. Jean CasnerChief Human Resources Officer, Senior Vice President$1.7m
- Mr. Jeffrey MannSenior Vice President, General Counsel, Product Development$3.0m
- Ms. Ginny BlockiSenior Vice President - Strategy
- Mr. Tom BlountSenior Vice President and President, North America
- Mr. Shaun CurtisSenior Vice President - Global Manufacturing, Supply Chain and Quality$2.1m
- Mr. Anthony RothVice President, Chief Accounting Officer, Corporate Controller
- Mr. Slobodan RadumiloSenior Vice President and President - International
- Dr. Claire PomeroyLead Independent Director$333,004
- Ms. Carrie AndersonIndependent Director$317,004
- Mr. Robert HombachIndependent Director$332,004
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 60
- Social
- 99
- Governance
- 44
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Embecta Corp employs 1850 employees in the Health Care sector.
- Embecta Corp's digital application assists diabetes management for users.
- Embecta Corp's safety pen needles prevent needlestick injuries during use.
Weaknesses
- Embecta Corp's IPO was on 21 March 2022 with 2200 employees.
- Embecta Corp's products are distributed through retail and hospitals only.
- Embecta Corp's headquarters is in Parsippany, New Jersey.
Opportunities
- Embecta Corp's portfolio includes pen needles, syringes, and safety devices.
- Embecta Corp's digital application supports diabetes management solutions.
- Embecta Corp's products are used in insulin injection treatments.
Threats
- Embecta Corp's products are single-use medical devices requiring frequent replacement.
- Embecta Corp's market is limited to diabetes treatment solutions.
- Embecta Corp's business model relies on medical device manufacturing.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.